Stay up-to-date with the Dr Reddys Stock Liveblog, your trusted source for real-time updates and thorough analysis of a ...

Hyderabad: Dr. Reddy’s Laboratories Ltd has announced an investment of Rs 565.4 crore in its step-down wholly owned ...

Indian generic drugs maker Dr Reddy's Laboratories posted a narrow miss of quarterly profit expectations on Wednesday, as it ...

Dr Reddy's Laboratories share price gained almost 3% in the morning trades on Thursday post Q1 results that were declared ...

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

Dr. Reddy’s Laboratories Limited (NYSE:RDY) is one of the Best Indian Stocks to Buy for Next 5 Years. Dr. Reddy’s ...

The company is going to announce results for the quarter ended June 30th, 2025 on July 23, 2025 after the board meeting.

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

Erez Israeli, CEO of Dr Reddys Laboratories, said that the company has no plans to shift manufacturing to the US unless it ...

DRL posted a 2 per cent YoY increase in PAT to Rs 1,417.8 crore for Q1 FY26, compared with Rs 1,392 crore in the year-ago ...

The focus has now shifted to Semaglutide, the GLP-1 agonist being pursued as a generic version of Ozempic/Wegovy.

Initially, Dr Reddy's will focus on launching the generic semaglutide in Canada, India, Brazil, Turkey, and other emerging ...